Advanced Viral Research Corporation
(OTCBB: ADVR)
YONKERS, N.Y.–(BUSINESS WIRE)–July 17, 2006–Advanced Viral Research Corp. (OTC Bulletin Board: ADVR – News) a bio-pharmaceutical company, announced today that effective June 27, 2006, the company has received US patent approval for treatment of rheumatoid arthritis by administering Product R (AVR118), a peptide-nucleic acid preparation. Rheumatoid arthritis, a chronic inflammatory illness, is an autoimmune disease in which the immune system attacks normal tissue components as if they were invading pathogens. This illness affects about one percent of the world’s population.
“We are excited that the US Patent Office has granted us with this important patent,” says Stephen M. Elliston, CEO and President of Advanced Viral Research. “With such a large population affected by rheumatoid arthritis, the commercial prospects for AVR118 may potentially be expanded to include patients suffering from this debilitating disease. This also comes at a time when the treatment options for RA have been limited significantly by the withdrawal of COX II inhibitors from the market.”
Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients’ lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. ADVR’s lead product, AVR118 (formerly known as Product R), represents a complex mixture of peptides, amino acids, nucleosides, nucleotides and nucleic acid bases that possesses, among other things, immunomodulatory activity. We believe it may be employed in the treatment of diseases and conditions such as: Various conditions associated with cancer; cachexia, or body wasting, in patients with acquired immune deficiency syndrome (AIDS), cancer, human immunodeficiency virus, or HIV, including AIDS as a combination therapy; type 2 diabetes; human papilloma virus, or HPV; and rheumatoid arthritis. ADVR is in clinical trials for treatment of cachexia (body wasting) in patients with AIDS.
Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described From time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable Agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future Events or circumstances or otherwise.
For further information regarding Advanced Viral Research Corp., please Visit our website at http://www.adviral.com.
Contact:
Equity Relations, Inc.
Richard Brown, 617-314-7379
staff@equityrelations.com
Source: Advanced Viral Research Corp.
View the StockGuru Profile for Advanced Viral Research Corporation:
http://www.stockguru.com/profiles/advr/
We Invite you to Visit the All New StockGuru Blog!
Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks.
Click HERE to visit the Blog, or go to:
http://stockguru.com/blog/
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC was compensated 158,000 shares from a non controlling third party for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.